Candel Therapeutics, Inc. - Common Stock, $0.01 par value (CADL)
CUSIP: 137404109
Q2 2022 13F Holders as of 30 Jun 2022
- Type / Class
- Equity / Common Stock, $0.01 par value
- Shares outstanding
- 72,977,477
- Total 13F shares
- 6,345,954
- Share change
- -328,072
- Total reported value
- $20,561,000
- Price per share
- $3.24
- Number of holders
- 21
- Value change
- -$1,159,878
- Number of buys
- 6
- Number of sells
- 10
Quarterly Holders Quick Answers
What is CUSIP 137404109?
CUSIP 137404109 identifies CADL - Candel Therapeutics, Inc. - Common Stock, $0.01 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 137404109:
Top shareholders of CADL - Candel Therapeutics, Inc. - Common Stock, $0.01 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
2.7%
|
1,972,226
|
$10,039,000 | — | 31 Mar 2022 | |
| Northpond Ventures, LLC |
13F
|
Company |
2.7%
|
1,935,215
|
$9,850,000 | — | 31 Mar 2022 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.5%
|
1,125,000
|
$5,726,000 | — | 31 Mar 2022 | |
| Sands Capital Alternatives, LLC |
13F
|
Company |
1.1%
|
811,737
|
$4,132,000 | — | 31 Mar 2022 | |
| Laura K. Aguilar |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,046,940
|
$2,742,246 | — | 06 May 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.56%
|
407,156
|
$2,073,000 | — | 31 Mar 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.18%
|
132,322
|
$674,000 | — | 31 Mar 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.1%
|
75,217
|
$382,000 | — | 31 Mar 2022 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.1%
|
75,000
|
$382,000 | — | 31 Mar 2022 | |
| 683 Capital Management, LLC |
13F
|
Company |
0.06%
|
40,929
|
$208,000 | — | 31 Mar 2022 | |
| STATE STREET CORP |
13F
|
Company |
0.04%
|
27,600
|
$140,000 | — | 31 Mar 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.02%
|
13,455
|
$68,000 | — | 31 Mar 2022 | |
| Kestra Advisory Services, LLC |
13F
|
Company |
0.02%
|
12,500
|
$64,000 | — | 31 Mar 2022 | |
| Empirical Asset Management, LLC |
13F
|
Company |
0.02%
|
12,000
|
$61,000 | — | 31 Mar 2022 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.01%
|
10,867
|
$55,000 | — | 31 Mar 2022 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.01%
|
10,510
|
$53,000 | — | 31 Mar 2022 | |
| Udi Meirav |
3/4/5
|
Director |
—
class O/S missing
|
48,822
|
$43,940 | — | 26 Jul 2021 | |
| SMITH ALAN E |
3/4/5
|
Director |
—
class O/S missing
|
32,548
|
$29,293 | — | 26 Jul 2021 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
4,651
|
$24,000 | — | 31 Mar 2022 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
3,387
|
$17,000 | — | 31 Mar 2022 | |
| UBS Group AG |
13F
|
Company |
0%
|
2,000
|
$10,000 | — | 31 Mar 2022 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
1,462
|
$7,000 | — | 31 Mar 2022 | |
| Nathan Caffo |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
6,000
|
$5,400 | — | 29 Jul 2021 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
610
|
$3,000 | — | 31 Mar 2022 | |
| High Net Worth Advisory Group LLC |
13F
|
Company |
0%
|
300
|
$2,000 | — | 31 Mar 2022 | |
| Quent Capital, LLC |
13F
|
Company |
0%
|
182
|
$1,000 | — | 31 Mar 2022 | |
| John J. Canepa |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
110,000
|
— | — | 28 Feb 2022 | |
| Susan B. Stewart |
3/4/5
|
Chief Regulatory Officer |
—
class O/S missing
|
20,000
|
— | — | 11 Apr 2022 |
Institutional Holders of Candel Therapeutics, Inc. - Common Stock, $0.01 par value (CADL) as of Q2 2022
As of 30 Jun 2022,
Candel Therapeutics, Inc. - Common Stock, $0.01 par value (CADL) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,345,954 shares.
The largest 10 holders included
Northpond Ventures, LLC, FRANKLIN RESOURCES INC, FMR LLC, Sands Capital Ventures, LLC, Point72 Asset Management, L.P., VANGUARD GROUP INC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, and STATE STREET CORP.
This page lists
21
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2022 vs Q1 2022 Across Filers
Q1 2022 holders
21
Q2 2022 holders
21
Holder diff
0
| Investor | Q1 2022 Shares | Q2 2022 Shares | Share Diff | Share Chg % | Q1 2022 Value $ | Q2 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.